Paper Details

  1. Home
  2. Paper Details

Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma.

Author: BhaskarBirbal, KassimAdetola, PatonVirginia E, WamstadKaren, WhiteDarrell, YiJing

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

While new treatments have improved outcomes for multiple myeloma, more options are needed. Bortezomib, a medication that blocks a specific cellular process, has shown effectiveness in treating multiple myeloma that hasn't responded to other therapies. This medication also inhibits the growth of new blood vessels, which is a process involved in the development of multiple myeloma.
Paper Details　
Original Abstract of the Article :
Newer systemic therapies have significantly advanced the treatment of multiple myeloma, but additional agents are needed. Bortezomib is a proteasome inhibitor with efficacy in relapsed/refractory multiple myeloma that inhibits tumor angiogenesis, a process that has been implicated in multiple myelom...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cncr.27745

データ提供：米国国立医学図書館（NLM）

Results from AMBER, a Randomized Phase 2 Study of Bevacizumab and Bortezomib Versus Bortezomib in Relapsed or Refractory Multiple Myeloma

This research delves into the challenging world of [multiple myeloma], a type of blood cancer that often relapses or becomes resistant to treatment. Much like a camel navigating a shifting desert landscape, researchers explored new treatment strategies to combat this disease. The study investigated the efficacy of combining [bevacizumab] with [bortezomib] in patients with relapsed or refractory multiple myeloma, compared to [bortezomib] alone. The researchers found that the combination therapy showed [promising results], suggesting a potential benefit for patients with this challenging disease. This research provides valuable insights into the potential of combining targeted therapies to improve treatment outcomes for multiple myeloma.

A New Direction in Multiple Myeloma Treatment: Combining Bevacizumab and Bortezomib

This study explores the potential of combining bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, with bortezomib, a proteasome inhibitor, for the treatment of relapsed or refractory multiple myeloma. The researchers found that the combination therapy showed promising results, suggesting a potential benefit for patients with this challenging disease.

Fighting Multiple Myeloma: Exploring New Treatment Strategies

This study highlights the ongoing efforts to develop effective treatment strategies for multiple myeloma, a challenging blood cancer. The research suggests that combining targeted therapies, such as bevacizumab and bortezomib, may offer a promising approach for improving treatment outcomes for patients with relapsed or refractory disease. This research encourages further investigation into the potential of combination therapies to enhance the fight against multiple myeloma.

Dr. Camel's Conclusion

This research, much like a camel navigating a vast desert of cancer research, explores new avenues for treating multiple myeloma. The study's findings suggest that combining bevacizumab with bortezomib may offer a promising approach for patients with relapsed or refractory disease. This research provides valuable insights into the potential of combination therapies to improve treatment outcomes and offers a glimmer of hope for patients facing this challenging disease. The journey towards effective cancer treatment continues, and this research marks a significant step forward in the quest for new and potent therapies.

Date :
  1. Date Completed 2013-02-20
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

22811009

DOI: Digital Object Identifier

10.1002/cncr.27745

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.